AI
MCRB icon

Atom Investors’s Seres Therapeutics MCRB Stock Holding History

Atom Investors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,166
Closed -$80K – 587
2024
Q1 		$80K Buy
+5,166
New +$111K 0.01% 533
2023
Q2 		– Sell
-4,519
Closed -$513K – 342
2023
Q1 		$513K Sell
4,519
-257
-5% -$27.8K 0.28% 99
2022
Q4 		$535K Sell
4,776
-665
-12% -$89.2K 0.27% 82
2022
Q3 		$699K Sell
5,441
-4,157
-43% -$426K 0.25% 127
2022
Q2 		$658K Buy
9,598
+7,599
+380% +$655K 0.29% 96
2022
Q1 		$285K Sell
1,999
-2,056
-51% -$316K 0.13% 146
2021
Q4 		$676K Buy
+4,055
New +$644K 0.11% 136

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Atom Investors's MCRB Position: Q2 2024 in Review

Atom Investors sold out of Seres Therapeutics (MCRB) in Q2 2024, closing a stake of 5,166 shares — an estimated $80K sold.

Atom Investors first reported a position in MCRB in Q4 2021 and held it in 7 quarters. The position peaked at $699K in Q3 2022. 93 funds tracked by Wall St. Rank hold MCRB as of Q2 2024.

  • Atom Investors reported no remaining Seres Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Atom Investors sold 5,166 Seres Therapeutics shares in Q2 2024, an estimated $80K.
  • Atom Investors first reported a position in Seres Therapeutics in Q4 2021 and held it in 7 quarters.
  • Atom Investors's Seres Therapeutics position peaked at $699K in Q3 2022.
  • 93 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2024.

Based on Atom Investors's 13F filing for Q2 2024, filed 14 Aug 2024.